MOTS-c After 65: What Geriatric Safety Evidence Is Missing

Age Evidence Requires People in the Age Group

The legacy page moved from aging biology to fall risk, kidney dose adjustment, immune effects, laboratory schedules, and a geriatric risk-benefit protocol. None came from an administered-human MOTS-c study in people over 65.

The International Council for Harmonisation states the evidence principle plainly:

“Patients entering clinical trials should be reasonably representative of the population that will be later treated by the drug.”

The issuer is the ICH E7 Expert Working Group in Studies in Support of Special Populations: Geriatrics, under “General Principle.” The guidance describes how geriatric drug evidence should be developed; it does not endorse MOTS-c or provide its dose.

For this guideline, geriatric patients are defined as age 65 or older, with explicit encouragement to include people 75 and older. A registry capped at age 65 cannot establish safety across that population.

The Geriatric Evidence Envelope

The envelope contains useful aging biology and an evidence standard. It does not contain a geriatric treatment cohort.

Why the Mouse Study Is Easy to Overread

Reynolds and colleagues reported that experimental MOTS-c treatment improved physical capacity in mice across age groups, including late-life mice. In the human portion, ten young male participants performed exercise, and researchers measured endogenous MOTS-c in muscle and circulation (PMID 33473109; DOI 10.1038/s41467-020-20790-0).

Those are two different experiments:

• old mice received an experimental intervention;
• young humans exercised and had their own peptide measured.

Combining them into “older humans tolerated MOTS-c” changes the study design and is not a valid inference.

What the Current Trial Does Not Resolve

NCT07505745 is a recruiting Phase 2a study in adults ages 18 to 65 with prediabetes and overweight or obesity. Its public record lists no results.

Even if a 65-year-old enrolls, the trial cannot yet establish:

• a safety profile for people in their seventies, eighties, or nineties;
• age-related pharmacokinetics;
• interaction rates in broad polypharmacy;
• dose adjustment for frailty, kidney disease, or liver disease; or
• a geriatric monitoring interval.

One boundary age is not a representative older-adult database.

Separate Age From the Variables That Travel With Age

Age can correlate with kidney function, liver function, body composition, frailty, cognition, multiple diagnoses, and concurrent medicines. It does not replace them.

The MOTS-c renal-impairment audit examines why endogenous CKD findings do not create an eGFR dose table. The age 50–64 dosing review explains why no age adjustment can be calculated without a validated starting dose, and the older-adult safety page maps safety uncertainty before the geriatric boundary.

Figure 2

What ICH E7 expects a drug program to show for older patients, and the MOTS-c status

Text version of this diagram

1. Enough older patients to compare: ICH E7: for drugs used in diseases present in, but not unique to, older people, a minimum of 100 older patients would usually allow detection of clinically important differences. MOTS-c: the only registered trial stops at age 65 and has posted no results.
2. How older bodies handle the drug: ICH E7: test whether pharmacokinetics differ from younger adults, including the effects of abnormal kidney or liver function. MOTS-c: FDA identified no clinical studies with pharmacokinetic data.
3. Other medicines and illnesses: ICH E7: interactions matter most for older patients, who are more likely to take other medicines, and patients with other illnesses should not be excluded unnecessarily. MOTS-c: FDA identified no clinical studies of any kind.
4. Where that leaves people over 65: No geriatric dose, monitoring schedule or interaction list can be built from the current record. Any of these would be invented.

Product Risk Is Not an Age-Specific Adverse Event

FDA's July 2026 review found no human exposure data for MOTS-c via any route and no clinical pharmacokinetic studies. It also raised concerns about injection-related immunogenicity, aggregation, peptide impurities, and inconsistent substance naming.

Those concerns apply to the evidence and product layer. They do not prove that older adults have a particular reaction, fall risk, or organ complication.

The Responsible Bottom Line

The defensible conclusion is narrow: older-mouse biology is interesting, but administered-human geriatric safety is uncharacterized. This page cannot supply a reduced dose, laboratory cadence, fall-prevention protocol, or “healthy older adult” exception.

Medical review of this revision is pending. ICH, FDA, trial investigators, institutions, and study authors do not endorse MOTS-c, HealthRX.com, or this page.